News Releases

OptimizeRx Reports First Quarter 2024 Financial Results

May 14, 2024 at 4:01 PM EDT
  • Q1 revenue of $19.7 million, increasing 51% year-over-year
  • Q1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%
  • Won 9 DAAP deals during Q1

WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.

Financial Highlights

  • Revenue in the first quarter of 2024 increased 51% to $19.7 million, as compared to $13.0 million in the same year ago period.
  • Gross profit in the first quarter of 2024 increased 64% year-over-year to $12.2 million, from $7.4 million during the first quarter of 2023.
  • GAAP net loss totaled $(6.9) million or $(0.38) per basic and diluted share in the first quarter, as compared to $(6.4) million or $(0.37) during the first quarter of 2023.
  • Non-GAAP net loss in the first quarter totaled $(2.0) million or $(0.11) per diluted share, as compared to $(1.6) million or $(0.09) per diluted share during the first quarter of 2023 (see definition of these non-GAAP measures and reconciliation to GAAP, below).
  • Adjusted EBITDA for the first quarter of 2024 came in at $(0.3) million compared to $(2.2) million in the same year ago period (see definition of this non-GAAP measure and reconciliation to GAAP, below).
  • Cash, cash equivalents and short-term investments totaled $15.2 million as of March 31, 2024 as compared to $13.9 million as of December 31, 2023.

Will Febbo, OptimizeRx CEO commented, “I am excited to announce first quarter results came in above expectations with revenue growing 51% year-over-year to $19.7 million. We've continued to see significant momentum, particularly around the utilization of DAAP, our AI-enabled platform we have been building over the last few years, and few peers have the scalability and quality we deploy. In addition, we have simplified our business as a tech forward platform, which creates a more attractive enterprise on all levels. We believe these dynamics are resulting in stronger profitability metrics for the Company and are resulting in improvements to our KPIs which is best evidenced by our Net Revenue Retention coming in at 116% for the first quarter.”

“The tone of conversations with our pharma customers is completely different today than 12 months ago," noted Steve Silvestro, President. "We continue to have success with our AI-enabled platform at a rate higher than expected internally with 9 additional DAAP wins in Q1 alone. The Company is experiencing a meaningfully better selling environment within the pharma end-market which is in contrast to what was seen in 2022 and the first half of 2023. We have enhanced our commercial team with the recent addition of highly experienced sales reps and we are very encouraged by the early cross selling activities post Medicx acquisition."

Key Performance Indicators (KPIs)* Rolling Twelve
Months Ended
  Rolling Twelve
Months Ended
  (in thousands, except percentages)
Average revenue per top 20 pharmaceutical manufacturer $ 2,537     $ 1,823  
Percent of top 20 pharmaceutical manufacturers that are customers   100 %     100 %
Top 20 pharmaceutical manufacturers as percent of total net revenues   65 %     59 %
Net revenue retention   116 %     86 %
Revenue per averages full-time employee (FTE) $ 641     $ 605  

2024 Financial Outlook

For the full year 2024, the Company is reiterating its 2024 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $11 million.

Conference Call

Date: Tuesday, May 14, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Conference ID: 13746273

Definition and Use of Non-GAAP Financial Measures
This earnings release includes a presentation of non-GAAP net loss and non-GAAP net loss per diluted share or non-GAAP EPS, and Adjusted EBITDA, all of which are non-GAAP financial measures.

The Company defines non-GAAP net loss as GAAP net loss with an adjustment, as applicable, to add back depreciation, amortization, amortization of debt issuance costs, stock-based compensation, acquisition expenses, severance expenses, income or loss related to the fair value of contingent consideration, gain or loss from the disposal of a business, asset impairment charges, other income (loss), and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net loss divided by the number of weighted average shares outstanding on a diluted basis. Adjusted EBITDA is defined as GAAP net loss with an adjustment, as applicable, to add back depreciation, amortization, interest, stock-based compensation, acquisition expenses, severance expenses, income or loss related to the fair value of contingent consideration, gain or loss from the disposal of a business, asset impairment charges, other income (loss), and deferred income taxes. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company’s business operating results over different periods of time.

The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP net loss, non-GAAP EPS and Adjusted EBITDA are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.

The table, “Reconciliation of Non-GAAP to GAAP Financial Measures,” included below, provides a reconciliation of Non-GAAP net loss, Non-GAAP EPS and Adjusted EBITDA for the three months ended March 31, 2024 and 2023. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance to the most directly comparable GAAP measures. Reconciliations for forward-looking figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Definition of Key Performance Indicators*
Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2023 revenue”. We previously used “The top 20 pharma companies by 2022 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average Full Time Employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent.

About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers.

For more information, follow the Company on TwitterLinkedIn or visit

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected Adjusted EBITDA and prospects. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, seasonal trends, our ability to maintain our contracts with electronic prescription platforms, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC

(in thousands except share and per share data)
  March 31,
  December 31,
Current assets      
Cash and cash equivalents $ 15,177     $ 13,852  
Accounts receivable, net   29,748       36,253  
Taxes receivable   1,036       1,036  
Prepaid expenses and other   2,390       3,190  
Total current assets   48,351       54,331  
Property and equipment, net   153       149  
Other assets      
Goodwill   78,357       78,357  
Other intangibles, net   14,882       15,198  
Tradename and customer relationships, net   33,596       34,198  
Operating lease right of use assets, net   527       573  
Security deposits and other assets   501       568  
Total other assets   127,863       128,894  
TOTAL ASSETS $ 176,367     $ 183,374  
Current liabilities      
Current portion of long-term debt $ 3,500     $ 2,000  
Accounts payable – trade   1,665       2,227  
Accrued expenses   7,278       7,706  
Revenue share payable   2,814       5,506  
Taxes payable   371       49  
Current portion of lease liabilities   233       222  
Deferred revenue   904       172  
Total current liabilities   16,765       17,881  
Non-current liabilities      
Long-term debt, net   32,413       34,231  
Lease liabilities, net of current portion   314       371  
Deferred tax liabilities, net   4,337       4,337  
Total liabilities   53,829       56,821  
Stockholders’ equity      
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at March 31, 2024 or December 31, 2023          
Common stock, $0.001 par value, 166,666,667 shares authorized, 19,921,879 and 19,899,679 shares issued at March 31, 2024 and December 31, 2023, respectively   20       20  
Treasury stock, $0.001 par value, 1,741,397 shares held at March 31, 2024 and December 31, 2023.   (2 )     (2 )
Additional paid-in-capital   193,677       190,793  
Accumulated deficit   (71,157 )     (64,258 )
Total stockholders’ equity   122,538       126,553  

(in thousands except share and per share data)
  For the Three Months Ended
March 31,
    2024       2023  
Net revenue $ 19,690     $ 13,003  
Cost of revenues, exclusive of depreciation and amortization presented separately below   7,486       5,570  
Gross profit   12,204       7,433  
Operating expenses      
General and administrative expenses   16,166       14,032  
Depreciation and amortization   1,067       464  
Total operating expenses   17,233       14,496  
Loss from operations   (5,029 )     (7,063 )
Other income (expense)      
Interest expense   (1,546 )      
Interest income   20       665  
Total other income (expense), net   (1,526 )     665  
Loss before provision for income taxes   (6,555 )     (6,398 )
Provision for income taxes   (344 )      
Net loss $ (6,899 )   $ (6,398 )
Weighted average number of shares outstanding – basic   18,170,108       17,094,676  
Weighted average number of shares outstanding – diluted   18,170,108       17,094,676  
Loss per share – basic $ (0.38 )   $ (0.37 )
Loss per share – diluted $ (0.38 )   $ (0.37 )

(in thousands)
  For the Three Months Ended
March 31,
    2024       2023  
Net loss $ (6,899 )   $ (6,398 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization   1,067       464  
Stock-based compensation   3,024       4,381  
Increase in bad debt reserve   132       128  
Amortization of debt issuance costs   182        
Changes in:      
Accounts receivable   6,373       3,862  
Prepaid expenses and other assets   800       (1,734 )
Accounts payable   (562 )     (261 )
Revenue share payable   (2,692 )     (623 )
Accrued expenses and other liabilities   (362 )     (476 )
Taxes payable   323        
Deferred revenue   732       571  
Purchase of property and equipment   (32 )     (29 )
Purchases of held-to-maturity investments         (56,927 )
Redemptions of held-to-maturity investments         55,600  
Capitalized software development costs   (121 )     (194 )
Cash paid for employee withholding taxes related to the vesting of restricted stock units   (140 )     (171 )
Proceeds from exercise of stock options         40  
Repayment of long-term debt   (500 )      
Cash paid for interest $ 1,350     $  
Cash paid for income taxes $ 21     $  

(in thousands, except share and per share data)
  Three Months Ended March 31,
    2024       2023  
Net loss $ (6,899 )   $ (6,398 )
Depreciation and amortization   1,067       464  
Stock-based compensation   3,024       4,381  
Severance expenses   419        
Amortization of debt issuance costs   182        
Acquisition expenses   243        
Non-GAAP net loss $ (1,964 )   $ (1,553 )
Non-GAAP net loss per share      
Diluted $ (0.11 )   $ (0.09 )
Weighted average shares outstanding:      
Diluted   18,170,108       17,094,676  

  Three Months Ended March 31,
    2024       2023  
Net loss $ (6,899 )   $ (6,398 )
Depreciation and amortization   1,067       464  
Provision for income taxes   344        
Stock-based compensation   3,024       4,381  
Severance expenses   419        
Acquisition expenses   243        
Interest (income) expense, net   1,526       (665 )
Adjusted EBITDA $ (276 )   $ (2,218 )

Primary Logo

Source: OptimizeRx Corporation